Zanubrutinib May Affect the Heart Less Than Ibrutinib and Acalabrutinib in CLL/SLL
Zanubrutinib to treat chronic lymphocytic leukemia or small lymphocytic lymphoma was linked with fewer cardiac adverse effects compared with ibrutinib and acalabrutinib.
Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab
Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.
Nurses Are “Critical Link” in Providing Patients With Education and Empathy
Oncology nurses provide patients with lung cancer the education and empathy needed to navigate treatment options and adverse event management.
Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma
Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.
AI-Powered Detection System for Skin Cancers Receives FDA Approval
The first real-time, non-invasive skin cancer evaluation system has received clearance from the FDA.
FDA Approves TIL Therapy for Unresectable or Metastatic Melanoma
Lifileucel is the first TIL therapy approved by the FDA for a solid tumor, specifically previously treated unresectable or metastatic melanoma.
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit
Cadonilimab Plus Chemo Provides Survival Benefit in Gastric/GEJ Cancer
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer
Frontline Durvalumab Regimen Improves PFS, Responses in Advanced Endometrial Cancer
